PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer at very low risk of metastasis
Publication: ASCO 2023, Abstract TPS615 Authors: Elise Deluche, Stefan Michiels, Daniele Fric, Christophe Perrin, Caroline Bailleux, Thomas Bachelot, Pascal Ko Kivok Yun, Gaetan De Rauglaudre, Marie-Ange Mouret-Reynier, Romauld Le Scodan, Ines Vaz-Luis, Magali Lacroix-Triki, Clara Guyonneau, Fabrice Andre
Read MorePROOFS-Registry: Trial in Progress, ESMO Breast 2023
ESMO Breast 2023, #120TiP Fischer et al.
Read MoreImPrint immune signature in 10,000 early stage breast cancer patients from FLEX Study
SABCS 2022, Poster ID: PD9-08 Authors: Brufsky et al.
Read MoreIDEAL Trial: MammaPrint Utility for Prediction of Extended Endocrine Therapy, SABCS 2022
IDEAL Trial, GS5-10, SABCS 2022 Authors: Liefers, et al.
Read MoreImpact of Neoadjuvant Endocrine Therapy on Tumor Transcriptome in Patients With Early-Stage Breast Cancer From the FLEX Trial
PUBLICATION: San Antonio Breast Cancer Symposium 2022 TITLE: Impact of neoadjuvant endocrine therapy on tumor transcriptome in patients with early-stage breast cancer from the FLEX trial AUTHORS: Mehran Habibi1, Danijela Jelovac1, Rima Couzi1, Cesar Agusto Santa-Maria1, Catherine Klein1, Marissa White1, Nivali Naik1, Jennifer Wei2, Yen Huynh2, Architha Ellappalayam3, Lisa Read More
FOCUS Trial: Validation of MammaPrint for ≥ 70yrs w/ UltraLow risk of distant recurrence
J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.
Read MoreSTO-5 Trial: 20-yr benefit from Adjuvant Goserelin & Tamoxifen, JCO 2022
Journal of Clinical Oncology, 40:4071-4082 Authors: Johansson et al.
Read More
